Adolescence: Challenges and responses
Sue V. McDiarmid – 24 October 2013
Idiopathic portal hypertension: Natural history and long‐term outcome
Sith Siramolpiwat, Susana Seijo, Rosa Miquel, Annalisa Berzigotti, Angeles Garcia‐Criado, Anna Darnell, Fanny Turon, Virginia Hernandez‐Gea, Jaume Bosch, Juan Carlos Garcia‐Pagán – 23 October 2013 – Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long‐tem outcome of IPH by retrospectively studying 69 biopsy‐proven cases of IPH. Mean duration of follow‐up was 6.7 ± 4.6 years.
Idiopathic portal hypertension: Natural history and long‐term outcome
Sith Siramolpiwat, Susana Seijo, Rosa Miquel, Annalisa Berzigotti, Angeles Garcia‐Criado, Anna Darnell, Fanny Turon, Virginia Hernandez‐Gea, Jaume Bosch, Juan Carlos Garcia‐Pagán – 23 October 2013 – Idiopathic portal hypertension (IPH) is a rare cause of intrahepatic portal hypertension. Data on natural history and prognosis of IPH are limited. We sought to describe the complications and long‐tem outcome of IPH by retrospectively studying 69 biopsy‐proven cases of IPH. Mean duration of follow‐up was 6.7 ± 4.6 years.
Reply
Stuart C Gordon, Eduardo Bruno Martins, Leland J. Yee – 21 October 2013
The ABCs of viral hepatitis that define biomarker signatures of acute viral hepatitis
Darragh Duffy, Rasha Mamdouh, Melissa Laird, Charlotte Soneson, Lenaig Le Fouler, Maï El‐Daly, Armanda Casrouge, Jérémie Decalf, Amal Abbas, Noha Sharaf Eldin, Magnus Fontes, Mohamed Abdel‐Hamid, Mostafa K. Mohamed, Mona Rafik, Arnaud Fontanet, Matthew L. Albert – 21 October 2013 – Viral hepatitis is the leading cause of liver disease worldwide and can be caused by several agents, including hepatitis A (HAV), B (HBV), and C (HCV) virus.
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers
Andrea Lisotti, Francesco Azzaroli, Marco Montagnani, Giuseppe Mazzella – 21 October 2013
Higher viral load, higher hepatitis B surface antigen clearance?
Gin‐Ho Lo – 21 October 2013
Preparing for the uncertain yet inevitable: Off‐label combinations of antiviral agents in hepatitis C virus
Andrew Aronsohn, Nancy Reau, Donald Jensen – 21 October 2013
Interleukin‐22, liver progenitor cells, and liver cancer
Dechun Feng – 21 October 2013
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
Bryan C. Fuchs, Yujin Hoshida, Tsutomu Fujii, Lan Wei, Suguru Yamada, Gregory Y. Lauwers, Christopher M. McGinn, Danielle K. DePeralta, Xintong Chen, Toshihiko Kuroda, Michael Lanuti, Anthony D. Schmitt, Supriya Gupta, Andrew Crenshaw, Robert Onofrio, Bradley Taylor, Wendy Winckler, Nabeel Bardeesy, Peter Caravan, Todd R. Golub, Kenneth K. Tanabe – 21 October 2013 – Hepatocellular carcinoma (HCC) is the most rapidly increasing cause of cancer‐related mortality in the United States.